Abstract
Twenty-five patients with prostatic cancer who, for varying reasons, underwent different neoadjuvant treatment before radical prostatectomy were studied retrospectively. Pre- and post-hormonal specimens were compared in 10 of these patients (so-called “reference group”). Another 10 patients (so-called “control-group”) were assessed, who were cross-matched for pathological staging, grading and age with the reference group but had no neoadjuvant hormonal treatment. There was a significant morphological cyto-histological regression in all patients on hormonal neoadjuvant therapy for at least 2 months, despite the fact that it was impossible to show a real down-staging, even if the percentage of pathologically confirmed clinical intracapsular stages rose from 53 to 63% in these cases. No significant difference was observed in the grading or the Gleason score between patients who underwent hormonal therapy and those who did not. Nor were there significant differences regarding operation times and intraoperative transfusion. A marked reduction in the proliferative acitivity of the neoplasms was shown, using Ki-67, in the reference group. There were no other significant differences in proliferative activity, ploidy, index of heteroploidy and hyperexpression of p53 between the two groups. Two patients in the reference group, who were p53 negative, became positive after one month of neoadjuvant hormonal treatment.
Get full access to this article
View all access options for this article.